Amnestix Develops Genetic Analysis System

Amnestix is a biopharmaceutical company that has developed a powerful analytical platform to identify genetic determinants that underlie neurological disorders. The company’s genetic analysis system is called whole-genome association, and functions by comparing the genome of healthy and ill patients at hundreds of thousands of positions in order to identify where disease-prone genomes differ from healthy genomes. The company has used its technology to identify a bioactive protein essential for memory function, termed KIBRA.

Amnestix is a biopharmaceutical company that has developed a powerful analytical platform to identify genetic determinants that underlie neurological disorders. The company’s genetic analysis system is called whole-genome association, and functions by comparing the genome of healthy and ill patients at hundreds of thousands of positions in order to identify where disease-prone genomes differ from healthy genomes. The company has used its technology to identify a bioactive protein essential for memory function, termed KIBRA. The company is currently developing therapeutics targeting KIBRA which are indicated to treat acute memory loss, as seen in Alzheimer’s disease. The company’s analytical platform is currently being used to study other neurological disorders, including schizophrenia.